96 related articles for article (PubMed ID: 1878679)
1. BAVC regimen in CR AML patients.
Meloni G; Vignetti M; De Fabritiis P; Petti MC; Pinto MR; Testi AM; Vegna ML; Mandelli F
Bone Marrow Transplant; 1991; 7 Suppl 2():134. PubMed ID: 1878679
[No Abstract] [Full Text] [Related]
2. Autologous bone marrow transplantation in patients with AML in second complete remission (CR).
Meloni G; De Fabritiis P; Amadori S; Petti MC; Pulsoni A; Sandrelli A; Mandelli F
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():207-8. PubMed ID: 2653505
[No Abstract] [Full Text] [Related]
3. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
Capria S; Latagliata R; Avvisati G; Breccia M; Cimino G; Diverio D; Petti MC; Meloni G
Bone Marrow Transplant; 2005 Jul; 36(1):83-4. PubMed ID: 15880128
[No Abstract] [Full Text] [Related]
4. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Meloni G; Vignetti M; Avvisati G; Capria S; Micozzi A; Giona F; Mandelli F
Bone Marrow Transplant; 1996 Oct; 18(4):693-8. PubMed ID: 8899182
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy.
Meloni G; De Fabritiis P; Carella AM; Mangoni L; Porcellini A; Marmont A; Mandelli F
Bone Marrow Transplant; 1990 Jan; 5(1):29-32. PubMed ID: 2404528
[TBL] [Abstract][Full Text] [Related]
6. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
de la Rubia J; Sanz GF; Martín G; Sempere A; Picón I; Carral A; Larrea L; Martínez J; Soler MA; Bonanad S; López F; Jarque I; Sanz MA
Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
[TBL] [Abstract][Full Text] [Related]
7. Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
Isnard F; Guiguet M; Laporte JP; Zunic P; Elloumi M; Chéron N; Deloux J; Van Den Akker J; Lesage S; Fouillard L; Aoudjhane M; Lopez M; Douay L; Gorin NC; Najman A
Bone Marrow Transplant; 2001 May; 27(10):1045-52. PubMed ID: 11438819
[TBL] [Abstract][Full Text] [Related]
8. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
9. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
11. [Autotransplantation in acute nonlymphoid leukemia].
Meloni G; Mandelli F
Haematologica; 1991 Jun; 76 Suppl 3():321-6. PubMed ID: 1752528
[No Abstract] [Full Text] [Related]
12. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
13. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. The EBMT Group Working Party for Autologous Bone Marrow Transplantation.
Reiffers J; Korbling M; Labopin M; Gorin NC
Bone Marrow Transplant; 1991; 7 Suppl 2():144. PubMed ID: 1678976
[No Abstract] [Full Text] [Related]
14. Allogeneic BMT versus autologous BMT in childhood acute lymphoblastic leukemia (ALL): an Italian cooperative study of vincristine (VCR), F-TBI and cyclophosphamide. AIEOP (Associazione Italiana Ematologia ed Oncologia Pediatrica) Italy.
Uderzo C; Coleselli P; Messina C; Dini G; Bonetti F; Andolina M; Bagnulo S; Miniero R; Rondelli R; Paolucci P
Bone Marrow Transplant; 1991; 7 Suppl 2():132. PubMed ID: 1878677
[No Abstract] [Full Text] [Related]
15. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Locatelli F; Labopin M; Ortega J; Meloni G; Dini G; Messina C; Yaniv I; Fagioli F; Castel V; Shaw PJ; Ferrant A; Pession A; Sociè G; Frassoni F;
Blood; 2003 Feb; 101(4):1611-9. PubMed ID: 12393725
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
18. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
[TBL] [Abstract][Full Text] [Related]
19. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM
Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
